Lilly Partners With UNICEF to Expand Pediatric Healthcare Access
NEW YORK and INDIANAPOLIS, May 14, 2026 Eli Lilly and Company and UNICEF USA announced a major global healthcare...
Alzheimer’s Disease ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy Healthcare Innovation Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody NSCLC Oncology oncology innovation oncology research Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
NEW YORK and INDIANAPOLIS, May 14, 2026 Eli Lilly and Company and UNICEF USA announced a major global healthcare...
INDIANAPOLIS, May 12, 2026 Eli Lilly and Company has reported positive results from two major late-phase obesity trials showing...
LEBANON, Indiana, United States – May 6, 2026 Eli Lilly and Company has announced an additional $4.5 billion investment...
EMERYVILLE, CALIFORNIA, April 29, 2026 Profluent has announced a strategic multi-program research collaboration with Eli Lilly and Company to...
INDIANAPOLIS, NEW YORK & CAMBRIDGE, Mass., April 27, 2026 Eli Lilly and Company has announced a definitive agreement to...
INDIANAPOLIS and BOSTON, Mass., April 20, 2026 Eli Lilly and Company has announced a landmark agreement to acquire Kelonia...
INDIANAPOLIS, April 16, 2026 Eli Lilly and Company announced positive results from its ACHIEVE-4 Phase 3 clinical trial, demonstrating...
Houston, Texas, U.S. | April 15, 2026 Eli Lilly and Company has announced a strategic agreement to acquire CrossBridge...
Indianapolis, Indiana | April 13, 2026 Eli Lilly and Company has announced positive topline results from the Phase 3...
INDIANAPOLIS, April 9, 2026 Eli Lilly and Company has announced the U.S. launch of Foundayoâ„¢ (orforglipron), a first-in-class oral...
